Factory 99% Nsi-189 Powder CAS 1270138-40-3 Nootropics Nsi-189

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: A1
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Name: Nsi-189
• Appearance: White Powder
• Grade: Pharmaceutical Grade
• Assay: 99%
• Function: Nootropics
• Sample: Available
• OEM: Available
• MOQ: 10g
• Transport Package: Foil Bag
• Specification: 99
• Trademark: /
• Origin: China
• Production Capacity: 10000 Kgs Per Month

Product Description

Product Name	NSI-189
Specification	99%
Appearance	White Powder
CAS	1270138-40-3
Molecular Formula	C22H30N4O

NSI-189 is a small molecule drug with clinical treatment for major depressive disorders and preclinical treatment for Angel-man syndrome, radiation-induced cognitive impairment, type 1 and type 2 diabetes, and stroke.

1. Neurodegenerative Disease Treatment: NSI-189 is being explored as a potential therapeutic for various neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and depression with neurodegenerative features.
2. Cognitive Enhancement: Due to its ability to stimulate neurogenesis and neuroplasticity, NSI-189 is being investigated for its potential to enhance cognitive function, memory, and learning abilities in healthy individuals or those with mild cognitive impairment.
3. Clinical Trials: It is currently undergoing clinical trials to evaluate its safety, efficacy, and optimal dosing regimen for treating specific neurological conditions.

1. Stimulates Neurogenesis: NSI-189 promotes the growth and differentiation of new neurons (neurogenesis) in the brain, particularly in the hippocampus, a region crucial for memory and emotion.
2. Enhances Neuroplasticity: By increasing the expression of brain-derived neurotrophic factor (BDNF), NSI-189 enhances neuroplasticity, the brain's ability to form new connections and adapt to changes, supporting cognitive resilience.
3. Antidepressant-like Effects: Early research suggests that NSI-189 may exert antidepressant effects through mechanisms distinct from traditional antidepressants, potentially addressing treatment-resistant depression and promoting emotional well-being.